

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A pharmaceutical composition comprising a benzodiazepine, wherein the composition is a dry powder for administration by pulmonary inhalation.

Claim 2 (currently amended): A pharmaceutical composition as claimed in claim 1, wherein the benzodiazepine is in the form of ~~either the~~ one of the following: the free base of the benzodiazepine, or and a pharmaceutically acceptable salt of the benzodiazepine.

Claim 3 (currently amended): A pharmaceutical composition as claimed in ~~either of the preceding claims~~ claim 1, wherein the benzodiazepine is selected from the group consisting of: clobazam or and clonazepam.

Claim 4 (currently amended): A pharmaceutical composition as claimed in ~~any one of the preceding claims~~ claim 1, wherein the composition has a less than 5 μ m fine particle fraction ($<5\mu\text{m}$) of at least 50%, ~~and preferably between 70 and 99% or between 80 and 99%.~~

Claim 5 (currently amended): A pharmaceutical composition as claimed in ~~any one of the preceding claims~~ claim 1, wherein the composition has a fine particle dose of between 50% and 90% of the composition, ~~and preferably between 60 and 70%.~~

Claim 6 (currently amended): A pharmaceutical composition as claimed in ~~any one of the preceding claims~~ claim 1, further comprising particles of ~~benzodiazepine~~ and a force control agent.

Claim 7 (currently amended): A pharmaceutical composition as claimed in claim 6, wherein the force control agent is selected from the group consisting of: an amino acid, or peptide, or

derivatives thereof, a phospholipid, ~~or~~ a metal stearate and a combination of any of the foregoing.

Claim 8 (currently amended): A pharmaceutical composition as claimed in claim 7, wherein the force control agent is selected from the group consisting of: leucine, lysine, cysteine, ~~or~~ and mixtures thereof.

Claim 9 (currently amended): A pharmaceutical composition as claimed in claim 6, wherein the force control agent is ~~included in an amount of~~ comprises up to 50% w/w, ~~preferably less than 10% w/w, and more preferably less than 5% w/w~~ of the composition.

Claim 10 (currently amended): A pharmaceutical composition as claimed in ~~any of the preceding claims~~ claim 1, wherein the composition comprises benzodiazepine particles having a MMAD of less than 10 μ m.

Claim 11 (currently amended): A pharmaceutical composition as claimed in claim 10, wherein the benzodiazepine particles have a MMAD of from 2 μ m to 5 μ m ~~2-5 μ m or a MMAD of less than 2 μ m.~~

Claim 12 (currently amended): A pharmaceutical composition as claimed in ~~any one of the preceding claims~~ claim 1, wherein the composition further comprises carrier particles, ~~preferably wherein the carrier particles have a particle size of at least 20 μ m.~~

Claim 13-17 (canceled)

Claim 18 (currently amended): A method of treating seizures comprising administering the composition of claim 1 via pulmonary inhalation ~~the administration of a therapeutically effective amount of a pharmaceutical composition as claimed in any one of claims 1-12~~ to a subject in need of such treatment, said composition comprising a therapeutically effective amount of the benzodiazepine.

Claim 19 (currently amended): A method of treating Acute Panic Disorder comprising administering the composition of claim 1 via pulmonary inhalation ~~the administration of a therapeutically effective amount of a pharmaceutical composition as claimed in any one of claims 1-12~~ to a subject in need of such treatment, said composition comprising a therapeutically effective amount of the benzodiazepine.

Claim 20 (currently amended): A method of sedating ~~or premedicating~~ a patient, comprising administering the composition of claim 1 via pulmonary inhalation ~~the administration of a therapeutically effective amount of a pharmaceutical composition as claimed in any one of claims 1-12~~ to a subject in need of such sedation ~~or premedication~~, said composition comprising a therapeutically effective amount of the benzodiazepine.

Claim 21 (new): A method of premedicating a patient, comprising administering the composition of claim 1 via pulmonary inhalation to a subject in need of such premedication, said composition comprising a therapeutically effective amount of the benzodiazepine.

Claim 22 (new): A pharmaceutical composition as claimed in claim 1, wherein the composition has a less than 5 μ m fine particle fraction of particles of between 70% and 99%.

Claim 23 (new): A pharmaceutical composition as claimed in claim 1, wherein the composition has a less than 5 μ m fine particle fraction of particles of between 80% and 99%.

Claim 24 (new): A pharmaceutical composition as claimed in claim 1, wherein the composition has a fine particle dose of between 60 % and 70% of the composition.

Claim 25 (new): A pharmaceutical composition as claimed in claim 6, wherein the force control agent comprises less than 10% w/w of the composition.

Claim 26 (new): A pharmaceutical composition as claimed in claim 6, wherein the force control agent comprises less than 5 % w/w of the composition.

Claim 27 (new): A pharmaceutical composition as claimed in claim 10, wherein the benzodiazepine particles have a MMAD of less than $2\mu\text{m}$.

Claim 28 (new): The composition of claim 12, wherein the carrier particles have a particle size of at least $20\mu\text{m}$.